Show simple item record

dc.contributor.authorAllen, Aaron M.en_US
dc.contributor.authorElshaikh, Mohameden_US
dc.contributor.authorWorden, Francis P.en_US
dc.contributor.authorBradford, Carol R.en_US
dc.contributor.authorTeknos, Theodoros N.en_US
dc.contributor.authorChepeha, Douglas B.en_US
dc.contributor.authorTsien, Christinaen_US
dc.contributor.authorDawson, Laura A.en_US
dc.contributor.authorUrba, Susanen_US
dc.contributor.authorWolf, Gregory T.en_US
dc.contributor.authorNormolle, Danielen_US
dc.contributor.authorEisbruch, Avrahamen_US
dc.date.accessioned2007-09-20T18:01:26Z
dc.date.available2008-04-03T18:46:50Zen_US
dc.date.issued2007-02en_US
dc.identifier.citationAllen, Aaron M.; Elshaikh, Mohamed; Worden, Francis P.; Bradford, Carol R.; Teknos, Theodoros N.; Chepeha, Douglas B.; Tsien, Christina; Dawson, Laura A.; Urba, Susan; Wolf, Gregory T.; Normolle, Daniel; Eisbruch, Avraham (2007). "Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer." Head & Neck 29(2): 137-142. <http://hdl.handle.net/2027.42/55903>en_US
dc.identifier.issn1043-3074en_US
dc.identifier.issn1097-0347en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/55903
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17111432&dopt=citationen_US
dc.description.abstractBackground. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m 2 /day and5-fluorouracil 600 mg/m 2 /day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid-treatment 1-week break. Results. Forty-six patients with T3-4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was −3.8% and −7.9%, respectively ( p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. Conclusions. In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients. © 2006 Wiley Periodicals, Inc. Head Neck, 2007en_US
dc.format.extent171529 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherCancer Research, Oncology and Pathologyen_US
dc.titleAcceleration of hyperfractionated chemoradiation regimen for advanced head and neck canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan ; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Biostatistics, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan ; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.identifier.pmid17111432en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/55903/1/20495_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/hed.20495en_US
dc.identifier.sourceHead & Necken_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record